Nasdaq:QDEL
QuidelOrtho Corp
A global leader in diagnostic testing solutions offering rapid infectious disease detection for healthcare systems and public health authorities worldwide.
Key Metrics
Investment Thesis
Bull Case
Investors might consider this stock if they believe the company can successfully refinance its debt structure and return to profitable operations as it exits one-time transaction costs. The diverse portfolio of diagnostic tests provides a stable revenue base that could grow with increasing global demand for infectious disease monitoring and pandemic preparedness. Strategic partnerships in emerging markets and potential new product launches in oncology or neurological disorders could unlock significant future growth potential.
Bear Case
The company's recent financial history shows persistent losses with a retained earnings deficit of $996M, indicating fundamental profitability challenges that have lasted for several years. The massive debt repayment of $2.29B has severely impacted liquidity and cash reserves, leaving the company vulnerable to interest rate hikes or credit rating downgrades. High operating expenses consuming over 80% of revenue suggest inefficient cost structures that are difficult to scale without significant margin improvement.
About QuidelOrtho Corp
QuidelOrtho Corp designs and manufactures diagnostic testing solutions primarily for infectious diseases, serving healthcare providers, laboratories, and public health agencies globally. The company specializes in rapid antigen tests, molecular diagnostics, and point-of-care devices used to detect conditions like HIV, Lyme disease, and various respiratory pathogens. Its market presence spans the United States, Europe, and Asia, with a focus on both commercial and government-funded testing programs.
Analysis
Management Discussion
Despite generating $2.73B in revenue, the company reported a net loss of $1.13B for 2025, primarily due to a massive $2.29B debt repayment event that distorted operating performance metrics. Operating expenses reached $2.19B against $2.73B in revenue, resulting in an operating profit deficit of $919.2M and a significant cash flow burn from investing activities of $192.7M. While operations generated positive cash flow from activities of $105.2M, the net change in cash was positive at $71.3M only due to financing inflows.
Industry Overview
The global diagnostics industry is experiencing steady growth driven by aging populations, emerging infectious diseases, and increased demand for point-of-care testing solutions. Regulatory bodies worldwide are tightening quality standards which favors established players with robust R&D pipelines and manufacturing capabilities. Consolidation trends in the sector provide opportunities for larger companies to acquire smaller niche players but also increase competitive pressure on pricing.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $3.00B | $2.78B | $2.73B |
| Cost of Revenue | $1.50B | $1.50B | $1.46B |
| Gross Profit | $1.49B | $1.29B | $1.27B |
| Operating Expenses | $1.36B | $3.25B | $2.19B |
| Operating Income | $139.1M | $-1.96B | $-919.2M |
| R&D | $246.8M | $218.7M | $186.2M |
| G&A | $763.2M | $766.8M | $746.3M |
| Stock-Based Comp | $51.6M | $42.1M | $45.9M |
| D&A | $457.2M | $453.4M | $442.0M |
| Amortization | $204.8M | $203.4M | $189.2M |
| Other OpEx | $345.3M | $2.26B | $1.26B |
| Non-Operating Income | $-168.2M | $-170.6M | $-188.5M |
| Interest Income | $5.5M | $2.6M | $2.2M |
| Pre-Tax Income | $-29.1M | $-2.13B | $-1.11B |
| Income Tax | $-19.0M | $-79.5M | $24.1M |
| Continuing Ops | $-10.1M | $-2.05B | $-1.13B |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-10.1M | $-2.05B | $-1.13B |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-10.1M | $-2.05B | $-1.13B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $1.31B | $1.22B | $1.45B |
| Cash & Equivalents | $118.9M | $98.3M | $169.8M |
| Marketable Securities | $48.4M | $0 | — |
| Accounts Receivable | $303.3M | $282.4M | $417.0M |
| Inventory | $577.8M | $533.7M | $577.6M |
| Prepaid Expenses | $262.1M | $262.4M | $250.5M |
| Other Current Assets | $0 | $42.1M | $32.4M |
| Long-Term Assets | $7.25B | $5.20B | $4.32B |
| PP&E (Net) | $1.44B | — | — |
| Intangibles | $2.93B | $2.74B | $2.56B |
| Goodwill | $2.49B | $649.5M | $0 |
| Operating Leases | $169.6M | $168.7M | $155.5M |
| LT Securities | $7.4M | $0 | — |
| Other LT Assets | $205.5M | $1.65B | $1.60B |
| Total Assets | $8.56B | $6.42B | $5.77B |
| Current Liabilities | $833.8M | $998.8M | $966.1M |
| Accounts Payable | $294.8M | $246.0M | $279.4M |
| Current Debt | $139.8M | $341.8M | $178.3M |
| Current Leases | $26.7M | $31.1M | $29.3M |
| Taxes Payable | $11.1M | $5.4M | $11.5M |
| Other Current Liab | $361.4M | $374.5M | $467.6M |
| Long-Term Liabilities | $2.72B | $2.44B | $2.88B |
| LT Operating Leases | $172.8M | $167.2M | $154.4M |
| Other LT Liab | $2.55B | $2.27B | $2.73B |
| Total Liabilities | $3.56B | $3.44B | $3.85B |
| Shareholders' Equity | $5.01B | $2.98B | $1.92B |
| Paid-In Capital | $2.85B | $2.88B | $2.93B |
| Retained Earnings | $2.19B | $135.8M | $-996.0M |
| AOCI | $-30.0M | $-36.2M | $-15.4M |
| Total L&E | $8.56B | $6.42B | $5.77B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-10.1M | $-2.05B | $-1.13B |
| Non-Cash Adjustments | $328.2M | $2.02B | $762.0M |
| Working Capital Changes | $-37.9M | $117.7M | $475.0M |
| Cash from Operations | $280.2M | $83.0M | $105.2M |
| Capital Expenditures | $209.3M | $195.1M | $188.2M |
| Cash from Investing | $-187.6M | $-149.9M | $-192.7M |
| Debt Repayments | — | — | $2.29B |
| Share Buybacks | $7.2M | $0 | $0 |
| Cash from Financing | $-265.8M | $48.8M | $155.8M |
| FX Effect | $-1.2M | $-2.9M | $3.0M |
| Net Change in Cash | $-174.4M | $-21.0M | $71.3M |
| Beginning Cash | $293.9M | $119.5M | $98.5M |
| Ending Cash | $119.5M | $98.5M | $169.8M |
Frequently Asked Questions
How does QuidelOrtho Corp make money?
The company generates revenue through three primary streams: Infectious Diseases diagnostics including HIV and sexually transmitted infections; Respiratory diagnostics covering flu, RSV, and emerging viral threats; and Other diagnostics encompassing Lyme disease and pregnancy tests. Additional revenue comes from the sale of testing devices, reagents, and consumables to hospital laboratories and point-of-care settings.
What are the main risks for QDEL?
Significant volatility in net income driven by large one-time debt repayments and high operating expenses relative to revenue growth. The company faces intense competition from generic manufacturers and alternative testing technologies that could erode pricing power and market share. Regulatory changes in key markets like the US or EU regarding diagnostic reimbursement and labeling requirements pose ongoing compliance risks. Heavy investment in research and development alongside substantial capital expenditures creates pressure on cash flow and liquidity.
What is QDEL's competitive advantage?
QuidelOrtho maintains a robust portfolio of patented technologies that provide high-sensitivity detection for multiple pathogens simultaneously. The company benefits from strong government relationships and established supply chains that ensure reliable distribution of critical diagnostic tools during public health emergencies. Its diversified product mix across infectious disease categories reduces reliance on any single test market, providing revenue stability.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.